Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
J Llovet, S Ricci, V Mazzaferro, P Hilgard… - Journal of clinical …, 2007 - ascopubs.org
LBA1 Background: HCC is the 3rd cause of cancer death globally with most deaths
occurring within 1 year of diagnosis. No standard therapy exists for advanced HCC …
occurring within 1 year of diagnosis. No standard therapy exists for advanced HCC …
Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
J Llovet, S Ricci, V Mazzaferro, P Hilgard… - Journal of Clinical …, 2007 - cir.nii.ac.jp
抄録< jats: p> LBA1</jats: p>< jats: p> Background: HCC is the 3rd cause of cancer death
globally with most deaths occurring within 1 year of diagnosis. No standard therapy exists for …
globally with most deaths occurring within 1 year of diagnosis. No standard therapy exists for …